Last reviewed · How we verify
Autologous Serum 20%
Autologous serum 20% is a topical ophthalmic preparation of the patient's own blood serum that provides growth factors and immunomodulatory components to promote corneal healing and reduce ocular surface inflammation.
Autologous serum 20% is a topical ophthalmic preparation of the patient's own blood serum that provides growth factors and immunomodulatory components to promote corneal healing and reduce ocular surface inflammation. Used for Severe dry eye syndrome, Corneal epithelial defects, Ocular surface disease.
At a glance
| Generic name | Autologous Serum 20% |
|---|---|
| Also known as | Autologus serum low concentration |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Autologous biological therapeutic |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The preparation is derived from the patient's own serum and contains naturally occurring growth factors (EGF, FGF, TGF-β), immunoglobulins, and other bioactive proteins that support epithelial cell proliferation and migration. When applied topically to the ocular surface, these components enhance corneal wound healing, reduce inflammation, and improve tear film stability in patients with severe dry eye or corneal epithelial defects.
Approved indications
- Severe dry eye syndrome
- Corneal epithelial defects
- Ocular surface disease
Common side effects
- Ocular irritation
- Infection risk (from preparation/handling)
- Allergic reaction
Key clinical trials
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) (PHASE1)
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (PHASE1, PHASE2)
- Stem Cell Transplantation for Patients With Multiple Myeloma (PHASE1)
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |